Vireo Secures DEA Registrations for 41 Florida Dispensaries, Trulieve Confirms Federal Approvals

By Nicolás Rodríguez, Managing Editor

Vireo Growth (CSE: VREO; OTCQX: VREOF) and Trulieve Cannabis (NYSE: TRLV) have confirmed receiving federal Drug Enforcement Administration (DEA) registrations for state-licensed medical marijuana operations, marking a significant development in the relationship between federal drug regulation and state cannabis markets.

Vireo announced November 2 that all 41 of its Florida medical cannabis dispensaries had received DEA registrations. Trulieve separately confirmed federal registrations for medical marijuana operations, although the company did not disclose the total number of facilities approved.

The announcements follow the Department of Justice’s initial issuance of federal registrations to more than 900 medical marijuana dispensaries across seven states.

The approvals establish a new federal compliance framework for participating medical cannabis businesses, but they do not constitute blanket authorization for all activities conducted under state cannabis licenses.

Vireo Secures Registrations Across Florida Network

Vireo’s announcement covers its 41 medical cannabis dispensaries in Florida, one of the country’s largest state-regulated medical marijuana markets.

The company said the registrations represent an important step toward operating within the emerging federal medical cannabis framework.

The approvals apply to the dispensaries identified in the company’s announcement. They should not be interpreted as confirmation that all of Vireo’s cultivation, processing, or distribution operations have received equivalent federal authorization.

Trulieve Confirms Federal Approvals

Trulieve also announced November 2 that it had obtained DEA registrations for state-licensed medical marijuana operations.

Unlike Vireo, the company did not provide a facility-by-facility breakdown or specify the total number of registrations.

Federal registration is tied to qualifying activities and facilities rather than automatically extending across an entire corporate organization.

For large multistate operators, the practical benefits will depend on which businesses and activities qualify, how federal requirements interact with state licensing, whether additional registrations become available, the costs of federal compliance, access to registered suppliers and distribution networks, potential tax implications under Section 280E, and the ability to integrate federally registered medical operations with existing state-regulated businesses.

Federal Registrations Bring New Compliance Requirements

The Department of Justice announced on October 30 that the DEA had begun issuing registrations to qualifying medical marijuana dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

The registrations implement part of an April 2026 federal framework that places certain qualifying medical marijuana activities under Schedule III controls. The broader proposal to reschedule marijuana remains a separate administrative proceeding.

According to the Justice Department, applicants must complete federal reviews before receiving registration. Approved dispensaries are subject to security, recordkeeping, inventory control, and other requirements governing controlled substances.

The DEA is also reviewing applications from medical marijuana manufacturers and distributors, which face additional requirements involving inspections, production controls, and quotas.

What the Registrations Mean for Cannabis Operators

Federal registration could provide participating companies with greater regulatory certainty, but the immediate commercial implications remain uncertain.

For Vireo and Trulieve, several issues will determine the significance of the approvals. The distinction between medical and recreational cannabis is particularly important. The Justice Department has explicitly stated that the new framework does not authorize adult-use marijuana activities or cannabis businesses operating outside its defined scope.

For investors, federal registration represents regulatory progress rather than an automatic improvement in profitability. The financial impact will depend on how the framework is implemented and whether companies can translate their new status into measurable operational benefits.

These developments will also shape discussions at IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where industry executives, regulators, cultivators, investors, and policymakers will examine the implications of federal cannabis reform.